JNJ-61393215 + ritonavir

JNJ-61393215 + ritonavir is an investigational combination consisting of JNJ-61393215, a novel, selective, high-affinity orexin-1 receptor (OX1R) antagonist, and ritonavir, a strong CYP3A inhibitor used as a pharmacokinetic enhancer. JNJ-61393215 is being developed for the adjunctive treatment of neuropsychiatric disorders, including major depressive disorder (MDD) with anxious distress, anxiety disorders, mood disorders, addictive behaviors, and potentially other indications. Ritonavir is used in this combination specifically to evaluate its effect on the pharmacokinetics (PK) of JNJ-61393215, as part of early-phase clinical studies, since ritonavir can inhibit CYP3A enzymes that may metabolize JNJ-61393215, potentially increasing its plasma concentration[1][7][9].